

Clinical Trial launched at Gold Coast Hospital

- The clinical trial has begun for up to 90 pregnancies for a period of six to nine months; with an objective to evaluate clinical usability, patient satisfaction, value for money and economic analysis;
- The Gold Coast Hospital and Health Service (GCHHS) manages more than 5,000 pregnancies per year and is currently undertaking an ambitious digital transformation program for the health service under their Digital 2024 (D24) strategic plan; and
- Both parties have signed an Innovation Collaboration and Project agreement to enable the clinical trial.

HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care, today announced the clinical trial at Gold Coast Hospital is now underway.

Milestones over the past months include:

- Established and collaborated with project team, project plan and key deliverables;
- Completed HeraCARE platform configuration, customisation, workflow integration and set up including care plans for pregnant women, to include remote vital measurements;
- Completed clinical, technical, and ‘train the trainer’ teams training and developed a HeraCARE training library with videos and manuals;
- HeraCARE and HeraBEAT environments testing before going live for pregnant women and clinicians;
- HeraBEAT devices delivered, and payments received for hardware and software;
- Onsite visit with HeraMED implementation team; and
- Go-Live with on-boarding pregnant women.

The launch of this clinical trial is an important step for HeraMED after such a rigorous and extensive process undertaken prior to the clinical trial beginning.

HeraMED Executive Vice-President ANZ, Anoushka Gungadin said: “During the past few months, both our teams have worked closely with a large group of stakeholders across Gold Coast health to bring the project to this stage. The depth and diligence of the work our teams have done in the last few months is truly impressive. I look forward to continuing to work closely with the team at Gold Coast to support, learn and adapt over the trial period that has now started.”

HeraMED Executive Chairman, Ron Weinberger said: “We are delighted to be launching this clinical trial at Gold Coast University Hospital which is a highly regarded leader in digital health innovation.

“Our collaboration to investigate HeraCARE for additional medical conditions is reflective of the unique nature of our platform and we are looking forward to working with the Gold Coast team on ways to adapt and customise the platform and our solution to accommodate remote monitoring for a broad range of medical conditions during pregnancy.”

About Gold Coast Hospital and Health Service (GCHHS)

GCHHS is an internationally recognised health institution that has embraced digital transformation and innovation to improve patient care and patient experience. GCHHS services a population of more than 600,000, with a patient catchment between the northern Gold Coast and the New South Wales border and a high annual number of visitors and tourists. GCHHS also provides services to patients in northern NSW, where those services are not provided within the area. Gold Coast Health manages more than 20 physical facilities including three hospitals and two health precincts. Gold Coast Hospital are proud to be Australia's first whole health service to receive Magnet Recognition for nursing and midwifery excellence and dedication to providing innovative, high-quality care.

About Gold Coast Digital Roadmap 'D24'

Gold Coast Health is splitting its digital roadmap, D24, across six key areas: virtual healthcare, data and analytics, digital liberation, digital assets, change management and digital literacy, and its ecosystem of essential technology partners.

Virtual healthcare is focused on cultivating the ability to deliver care that isn't contingent on the physical placement of the patient and the clinician - everything that doesn't require a face-to-face interaction in a clinic including for example telehealth and remote patient monitoring.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited

Executive Chairman

Dr Ron Weinberger

M: +61 406 384 189

E: ron@hera-med.com

Company Secretary

Jonathan Hart

E: Jonathan@hera-med.com

Investor Relations

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.